The CIRSE Registry for SIR-Spheres Therapy (CIRT)
Radioembolisation is a rapidly growing treatment modality in Europe. Previous reports on the safety and efficacy of this procedure for the treatment of primary and secondary liver tumours are very promising, but more evidence on the treatment in a clinical setting is necessary. In order to further improve our understanding of this therapy, CIRSE initiated a registry that enables robust data collection on the real-life clinical application of SIR-Spheres microspheres: the CIRSE Registry for SIR-Spheres Therapy (CIRT).
The CIRSE Registry for SIR-Spheres Therapy (CIRT) is a European-wide registry that aims to prospectively collect data on SIR-Spheres therapies. Various European medical centres already use this therapy to treat liver tumours. While smaller studies have shown that this treatment can have a positive effect, the registry aims to investigate the real-life application of SIR-Spheres microspheres on a multinational scale. Recruitment for this registry will commence in the course of 2014.
• Endpoints: The research objective is to prospectively collect data on patients with primary or secondary liver tumours who are treated with SIR-Spheres microspheres. CIRT aims to capture as broad a spectrum of data as feasible in order to understand the real-life application of radioembolisation with SIR-Spheres microspheres. Furthermore, CIRT aims to collect data on the Quality of Life of patients treated with SIR-Spheres microspheres. Because of its exploratory nature, no specific end points are formulated, but research questions will be formulated in the course of the registry. Please refer to the Project Overview for more information.
• Methods: Data will be collected prospectively from medical centres throughout Europe that have a certain minimum amount of experience with radioembolistation to exclude operators that are still in the learning phase of the procedure. The registry is planned to run for a minimum of five years, therefore ensuring that it does not only collect data on the initial treatment, but also on the long-term effects of radioembolisation. Furthermore, with the growing importance of palliative care in interventional oncology, the Steering Committee decided to include a quality of life questionnaire developed by the experts at the European Organisation for Research and Treatment of Cancer (EORTC): the QLQ-C30, a multilingually verified base questionnaire, together with its HCC Module, a module especially developed to capture liver cancer specific quality of life elements.
If you are a participating hospital you can